Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

[Pharmacovigilance update].

Livio F.

Rev Med Suisse. 2013 Jan 9;9(368):72-5. Review. French.

PMID:
23367709
2.
3.

Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions.

Angeli F, Reboldi G, Mazzotta G, Poltronieri C, Garofoli M, Ramundo E, Biadetti A, Verdecchia P.

Curr Drug Saf. 2012 Feb;7(1):76-85. Review.

PMID:
22663961
4.

Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension.

Riccioni G, Vitulano N, D'Orazio N, Bellocci F.

Adv Ther. 2009 Jul;26(7):700-10. doi: 10.1007/s12325-009-0050-5. Epub 2009 Jul 27. Review.

PMID:
19649581
5.

Aliskiren: beyond blood pressure reduction.

Riccioni G, Vitulano N, Zanasi A, Bellocci F, d'Orazio N.

Expert Opin Investig Drugs. 2010 Oct;19(10):1265-74. doi: 10.1517/13543784.2010.514902. Review.

PMID:
20812878
6.

Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.

Dalla Vestra M, Simioni N, Masiero A.

Minerva Endocrinol. 2009 Dec;34(4):333-8. Review.

PMID:
20046162
7.

Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases.

Yarows SA.

Expert Rev Cardiovasc Ther. 2010 Jan;8(1):19-33. Review.

PMID:
20030022
8.

Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.

Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL.

Hypertens Res. 2009 Mar;32(3):169-75. doi: 10.1038/hr.2008.21. Epub 2009 Jan 23.

PMID:
19262478
9.

Direct renin inhibition: an evaluation of the safety and tolerability of aliskiren.

Rashid H.

Curr Med Res Opin. 2008 Sep;24(9):2627-37. doi: 10.1185/03007990802336541 . Epub 2008 Aug 6. Review.

PMID:
18687166
10.

Aliskiren.

Brown MJ.

Circulation. 2008 Aug 12;118(7):773-84. doi: 10.1161/CIRCULATIONAHA.108.787630.

11.

[Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].

Horký K.

Vnitr Lek. 2010 Feb;56(2):120-6. Review. Czech.

PMID:
20329582
12.

Renin inhibitors.

Fisher ND, Meagher EA.

J Clin Hypertens (Greenwich). 2011 Sep;13(9):662-6. doi: 10.1111/j.1751-7176.2011.00514.x. Epub 2011 Jul 27. Review.

13.

Dabigatran.

Murphy L, Lawler L, Kavanagh EC.

AJNR Am J Neuroradiol. 2011 Nov-Dec;32(10):E195. doi: 10.3174/ajnr.A2850. No abstract available.

14.

Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.

Dietz R, Dechend R, Yu CM, Bheda M, Ford J, Prescott MF, Keefe DL.

J Renin Angiotensin Aldosterone Syst. 2008 Sep;9(3):163-75. doi: 10.1177/1470320308096411.

PMID:
18957387
15.
16.

Managing cardiovascular and renal risk: the potential of direct renin inhibition.

Sever PS, Gradman AH, Azizi M.

J Renin Angiotensin Aldosterone Syst. 2009 Jun;10(2):65-76. doi: 10.1177/1470320309104662. Review.

PMID:
19502253
17.

Renin inhibition in hypertension.

Gradman AH, Kad R.

J Am Coll Cardiol. 2008 Feb 5;51(5):519-28. doi: 10.1016/j.jacc.2007.10.027. Review.

18.

Aliskiren in the management of hypertension.

Barrios V, Escobar C.

Am J Cardiovasc Drugs. 2010;10(6):349-58. doi: 10.2165/11584980-000000000-00000. Review.

PMID:
21090828
19.

Aliskiren, the future of renin-angiotensin system blockade?

Uresin Y, Mehtar Bozkurt M, Sabirli S, Ozunal ZG.

Expert Rev Cardiovasc Ther. 2007 Sep;5(5):835-49. Review.

PMID:
17867914
20.

[Pharmacological sheet. Dabigatran, oral administration (Pradaxa)].

Duh PD, Leuckx PS, Warnez PM.

J Pharm Belg. 2012 Mar;(1):37-8. Review. French. No abstract available.

PMID:
22536682

Supplemental Content

Support Center